HU Group’s wholly-owned subsidiary Fujirebio has announced the acquisition of assays developer ADx NeuroSciences in a deal valued at $42.12m (€40m).

Founded in 2011, ADx NeuroSciences specialises in developing neurodegenerative biomarkers, tailor-made antibodies, and assays for in vitro diagnostics (IVD) and pharmaceutical companies.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The transaction, which is subject to the satisfaction of certain customary closing conditions, is anticipated to be concluded next month.

Upon completion of the deal, ADx NeuroSciences will become a wholly-owned subsidiary of Fujirebio Europe.

ADx NeuroSciences will continue to serve its existing partners and customers while expanding its portfolio of advanced biomarkers and antibodies that help in detecting neurodegenerative diseases, such as Parkinson’s and Alzheimer’s.

Fujirebio is engaged in developing, producing and commercialising robust IVD testing products across the world.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Through this transaction, the company will combine its expertise in high-quality IVD as well as its strategic CDMO partnerships with ADx NeuroSciences’ experience and biomarker portfolio to bring earlier neurodegenerative disease diagnostic solutions to the global diagnostics market.

Fujirebio stated that the deal will also add further experience, expertise and resources to the Fujirebio Neuro Center of Excellence.

Fujirebio president and CEO Goki Ishikawa said: “By welcoming ADx NeuroSciences in the Fujirebio group of companies, Fujirebio will be able to expand its antibody supply business and contract development and manufacturing (CDMO) offerings in the neurodegenerative field to our partners globally.

“Fujirebio is committed to invest in developing diagnostic kits in the field of neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease.”

In March, Fujirebio launched the Lumipulse G pTau 181 Plasma assay for fully automated blood-based Alzheimer’s disease biomarker testing.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact